Decade in review: a new era for RET-rearranged lung cancers
| Autor: | Noura J. Choudhury, Alexander Drilon |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
congenital hereditary and neonatal diseases and abnormalities endocrine system endocrine system diseases medicine.medical_treatment Cell non-small cell lung cancer (NSCLC) medicine.disease_cause Targeted therapy 03 medical and health sciences 0302 clinical medicine medicine ROS1 Lung cancer neoplasms business.industry Kinase Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions Thyroid medicine.disease 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Cancer research business Carcinogenesis |
| Zdroj: | Transl Lung Cancer Res |
| ISSN: | 2226-4477 2218-6751 |
| Popis: | Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first identified more than thirty years ago, targeted therapy for RET fusion-positive lung cancers was only explored in the last decade. Whereas repurposed multikinase inhibitors were initially tested, selective inhibitors RET inhibitors have dramatically improved outcomes for patients whose tumors harbor these alterations. In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers. While resistance to selective RET inhibition has been described, next-generation RET inhibitors are already being explored for patients who progress on prior RET kinase inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|